Spark eyes installment plan for $1M gene therapy; Pharma sales to hit $1.3T by 2018, report says;

> As a pricey gene therapy for blindness nears the market--some expect a cost of $1 million--its maker, Spark Therapeutics, is working with payers on long-term payment options, including pay-for-performance models. Report

> Global pharma sales are projected to grow to $1.3 trillion by 2018, Thomson Reuters says, as more brand-new drugs win approval, particularly in cancer. Report

> Me-too drugs may be due for an image overhaul now that competitive rivalries are helping bring down prices in some areas. Report

> Specialty pharmacy Diplomat ($DPLO) signed up to dispense AstraZeneca's ($AZN) cancer treatment Iressa, which recently won FDA approval for first-line, non-small cell lung cancer treatment. Report

> GlaxoSmithKline ($GSK) rolled out a new Sensodyne campaign in India. Report

> NattoPharma and TG Montgomery partnered up to take the vitamin brand MenaQ7 into Sweden. Report

> Turing Pharmaceuticals bought marketing rights to Daraprim (pyrimethamine) from Impax Laboratories ($IPXL) in a focus on toxoplasmosis and other infectious diseases. Report

And Finally... Roche ($RHHBY) brought in 100 European students for a music and drama festival to explore the intersection of science and music. Release

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.